Education
About Us
Working with TipRanks
Follow Us
PYC Therapeutics Limited (AU:PYC)
ASX:PYC
RESEARCH TOOLSreports
PYC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.95 - AU$2.09
Previous CloseN/A
Volume307.79K
Average Volume (3M)521.79K
Market Cap
AU$758.24M
Enterprise ValueAU$568.14M
Total Cash (Recent Filing)AU$49.25M
Total Debt (Recent Filing)AU$1.21M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Sep 02, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding583,260,440
10 Day Avg. Volume429,464
30 Day Avg. Volume521,793
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.07Price Target Upside60.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPYC-003 is now being assessed in a Phase I in healthy volunteers, entering a catalyst-rich period across all of its clinical programs.
Market ValidationNVS Acquisition of RGLS Further Validates MOA for Potentially Best-in-Class PYC-003.
ValuationThe upfront payment of US$7.00 per share infers an EV of US$0.8B – if applied to PYC’s capital structure, this generates a PYC valuation of AU$2.35 per share (US$1.50).
Bears Say
Competition And Market DynamicsAnalyst's recommendation is based on discounted, risk-adjusted multiples of 5 year forecast sales of the company’s three clinical candidates.
Probability Of SuccessApplying a 15% probability to the CVR, increases the valuation to AU$2.70 (US$1.72).
Speculative RiskBloom Burton is initiating research coverage of genetic medicine company, PYC Therapeutics, with a BUY rating (Speculative risk).
PYC Therapeutics Limited News
PYC FAQ
What was PYC Therapeutics Limited’s price range in the past 12 months?
PYC Therapeutics Limited lowest share price was AU$0.95 and its highest was AU$2.09 in the past 12 months.
What is PYC Therapeutics Limited’s market cap?
PYC Therapeutics Limited’s market cap is AU$758.24M.
When is PYC Therapeutics Limited’s upcoming earnings report date?
PYC Therapeutics Limited’s upcoming earnings report date is Sep 02, 2025 which is in 4 days.
How were PYC Therapeutics Limited’s earnings last quarter?
PYC Therapeutics Limited released its earnings results on Feb 27, 2025. The company reported -AU$0.055 earnings per share for the quarter, missing the consensus estimate of -AU$0.042 by -AU$0.013.
Is PYC Therapeutics Limited overvalued?
According to Wall Street analysts PYC Therapeutics Limited’s price is currently Undervalued.
Does PYC Therapeutics Limited pay dividends?
PYC Therapeutics Limited does not currently pay dividends.
What is PYC Therapeutics Limited’s EPS estimate?
PYC Therapeutics Limited’s EPS estimate is -0.08.
How many shares outstanding does PYC Therapeutics Limited have?
PYC Therapeutics Limited has 583,260,440 shares outstanding.
What happened to PYC Therapeutics Limited’s price movement after its last earnings report?
PYC Therapeutics Limited reported an EPS of -AU$0.055 in its last earnings report, missing expectations of -AU$0.042. Following the earnings report the stock price went up 3.279%.
Which hedge fund is a major shareholder of PYC Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PYC
PYC Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$2.07 (60.47% Upside)
AU$2.07 (60.47% Upside)
Blogger Sentiment
Bullish
AU:PYC Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.87%
12-Months-Change
Fundamentals
Return on Equity
-112.97%
Trailing 12-Months
Asset Growth
71.61%
Trailing 12-Months
Company Description
PYC Therapeutics Limited
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders, including Motor Neurone Disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
PYC Stock 12 Month Forecast
Average Price Target
AU$2.07
▲(60.47% Upside)
Technical Analysis
Opthea
―
Clinuvel Pharmaceuticals
―
Immutep Ltd
―
Clarity Pharmaceuticals Ltd.
―
Botanix Pharmaceuticals Limited
―
Ownership Overview
32.01% Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
67.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---